Myasthenia Gravis (MG) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Myasthenia Gravis (MG) Emerging Therapy and TPP Insights

Thelansis’s “Myasthenia Gravis (MG) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Myasthenia Gravis (MG) Overview

Myasthenia gravis is an autoimmune disorder in which the immune system produces antibodies that disrupt communication between nerves and muscles, causing fluctuating weakness that can affect the eyes, face, throat, limbs, and, in severe cases, breathing. For decades, treatment relied heavily on broad immune suppression through corticosteroids and related agents, which controlled symptoms but carried substantial long-term side effects. That has changed with two new classes of precision therapy targeting the specific immune mechanisms driving the disease rather than suppressing the immune system broadly, one blocking a receptor responsible for recycling harmful antibodies and the other interrupting a separate pathway that damages the nerve-muscle junction directly. Several agents within each class are now approved, giving physicians the ability to switch options when one is not well tolerated, and some therapies specifically address a less common antibody subtype that previously had fewer treatment options. These newer therapies are generally used alongside, rather than replacing, established immune-modulating treatment, with research now expanding toward B-cell targeted approaches.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Myasthenia Gravis (MG) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026